Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check6 days agoChange DetectedPublication added to the Publications section: Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis, Paediatr Drugs, 2026 Apr 2 (Online ahead of print).SummaryDifference0.0%

- Check14 days agoChange DetectedAdded a new publication citation to the Publications section: 'Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis' Am J Clin Dermatol. 2026 Mar 28.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.4.2 to v3.5.0.SummaryDifference0.0%

- Check64 days agoChange Detected- Revision label updated from v3.4.1 to v3.4.2. No substantive content changes to the page.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page shows a revision update from v3.4.0 to v3.4.1 with no visible changes to core content or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check78 days agoChange DetectedShow glossary added; minor capitalization changes to QC-related labels; and the revision number updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.